



San Diego, CA & Boston, MA, May 8, 2009 - BioLegend, a provider of antibodies and reagents for biomedical research, has been selected by the Harvard Immunology Executive Committee as the preferred vendor to more than 100 immunology research laboratories of the Harvard Immunology Program, labs that belong to Harvard Medical School and several affiliated hospitals and institutions. This arrangement provides Harvard immunologists, as well as other Harvard researchers, with access to over 8,000 antibodies and reagents at attractive pricing, as well as special bulk pricing, custom services, free shipping, custom assay development technology, and same day pickup service at the Biopolymers Facility. BioLegend will also collaborate with Harvard immunologists to commercialize immunology research reagents developed at Harvard.

“BioLegend is privileged to be a preferred vendor and we are honored to make our high quality, broad product line more accessible to Harvard immunology researchers. We look forward to helping laboratories maximize their budgets during these more difficult economic times,” commented Gene Lay, founder and CEO of BioLegend.

“There is great interest in the potential of this agreement, which should significantly facilitate our research as well as support new technological development,” said Christopher Carman, Ph.D., of the Division of Molecular and Vascular Medicine and a member of the Harvard committee which discussed this program.

About BioLegend

BioLegend develops and manufactures world-class, cutting-edge antibodies and reagents at an outstanding value to customers for biomedical research. The broad product portfolio includes flow cytometry, cell biology, and functional reagents for research in immunology, cancer research, stem cells, and more. The aggressive product development program is accomplished through technology licensing, collaborations, and internal research. BioLegend offers a wide range of custom services including assay development, sample testing, and conjugation. BioLegend was incorporated in June, 2002 with headquarters in San Diego. Its executive group includes co-founders and many scientists from PharMingen, now a part of BD Biosciences.

For more information, please visit www.biolegend.com.

Contact: Brad Kraft
President
(619) 994-2302
bkraft@biolegend.com.